Skip to Content

Akari Therapeutics, Plc [NASDAQ: AKTX]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Akari Therapeutics, Plc

Oklahoma City, OK (May 15, 2017) – On May 12, 2017, a securities class action lawsuit was filed in the United States District Court for the Southern District of New York against Akari Therapeutics, Plc (NASDAQ: AKTX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is March 30, 2017 through May 11, 2017. More specifically, this litigation was filed because throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company’s CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; (2) that the Company lacked adequate checks and protections to prevent such behavior; and (3) that, as a result of the foregoing, Defendants’ statements about Akari’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On May 11, 2017, the Company announced that its CEO, Dr. Gur Roshwalb, was placed on administrative leave while the Akari Board of Directors investigates whether Dr. Roshwalb had any involvement with a research report that contained material inaccuracies. On this news, the Company’s share price fell more than 20% during intraday trading on May 12, 2017.

Plaintiff seeks to recover damages on behalf of all Akari Therapeutics, Plc shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, July 11, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.

let’s connect

Click Here to Complete Federman & Sherwood Fee Agreement.


10205 North Pennsylvania Avenue
Oklahoma City, Oklahoma 73120

TEXAS Office

212 W. Spring Valley Road,
Richardson, Texas 75081